Christoph L. Driessen

Cantonal Hospital St. Gallen
Sankt Gallen, SG, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP
Published: May 13, 2026

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

Journal: American journal of hematology
Published: April 09, 2026

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Journal: ESMO open
Published: January 08, 2026

Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis.

Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis.

Journal: EClinicalMedicine
Published: December 01, 2025

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.

Journal: Swiss medical weekly
Published: October 23, 2025

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Journal: Haematologica
Published: September 23, 2025

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

Journal: HemaSphere
Published: September 01, 2025

BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study.

BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study.

Journal: Leukemia & lymphoma
Published: July 21, 2025

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Journal: Clinical epigenetics
Published: July 03, 2025

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.

Journal: Cancers
Published: June 29, 2025

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

Journal: HemaSphere
Published: June 16, 2025

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.

Journal: Nature reviews. Clinical oncology
Published: June 05, 2025
Showing 1-12 of 108

Last Updated: 09/26/2026